Beam Therapeutics Inc. (NASDAQ:BEAM – Get Rating) insider Fmr Llc sold 19,466 shares of the company’s stock in a transaction on Wednesday, April 13th. The stock was sold at an average price of $50.41, for a total value of $981,281.06. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Shares of Beam Therapeutics stock opened at $46.40 on Friday. Beam Therapeutics Inc. has a one year low of $46.40 and a one year high of $138.52. The business has a 50-day simple moving average of $62.29 and a 200 day simple moving average of $74.40.
Beam Therapeutics (NASDAQ:BEAM – Get Rating) last released its quarterly earnings results on Monday, February 28th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.01). Beam Therapeutics had a negative net margin of 714.91% and a negative return on equity of 52.28%. During the same period last year, the company posted ($1.69) EPS. Analysts expect that Beam Therapeutics Inc. will post -4.4 EPS for the current fiscal year.
BEAM has been the subject of a number of recent analyst reports. Guggenheim initiated coverage on Beam Therapeutics in a report on Wednesday, January 5th. They set a “buy” rating and a $130.00 price target for the company. SVB Leerink increased their price target on Beam Therapeutics from $116.00 to $121.00 and gave the stock an “outperform” rating in a report on Monday, January 10th. Finally, Wedbush decreased their price target on Beam Therapeutics from $159.00 to $152.00 and set an “outperform” rating for the company in a report on Monday, February 28th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Beam Therapeutics has a consensus rating of “Buy” and a consensus price target of $126.33.
About Beam Therapeutics (Get Rating)
Beam Therapeutics Inc, a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia.
- Get a free copy of the StockNews.com research report on Beam Therapeutics (BEAM)
- UiPath Stock is Nearing Rock Bottom Down Here
- Array Technologies Stock Giving Another Ground Floor Entry
- 3 Undervalued S&P 500 Stocks to Buy Now
- 3 Undervalued Easter Eggs to Watch For This Earnings Season
- Lululemon Rises On Wave Of Price Target Increases
Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.